Head to Head Survey: ShockWave Medical (NASDAQ:SWAV) and Quoin Pharmaceuticals (NASDAQ:QNRX)

Quoin Pharmaceuticals (NASDAQ:QNRX – Get Rating) and ShockWave Medical (NASDAQ:SWAV – Get Rating) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, earnings, dividends, profitability, analyst recommendations, valuation and risk.

Profitability

This table compares Quoin Pharmaceuticals and ShockWave Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Quoin Pharmaceuticals	N/A	-1,295.41%	-207.84%
ShockWave Medical	44.10%	59.99%	45.20%

Institutional & Insider Ownership

12.1% of Quoin Pharmaceuticals shares are owned by institutional investors. Comparatively, 90.6% of ShockWave Medical shares are owned by institutional investors. 36.6% of Quoin Pharmaceuticals shares are owned by company insiders. Comparatively, 3.9% of ShockWave Medical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Quoin Pharmaceuticals and ShockWave Medical’s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quoin Pharmaceuticals	N/A	N/A	-$21.46 million	N/A	N/A
ShockWave Medical	$489.73 million	14.30	$216.00 million	$5.70	33.67

ShockWave Medical has higher revenue and earnings than Quoin Pharmaceuticals.

Analyst Ratings

This is a summary of current recommendations for Quoin Pharmaceuticals and ShockWave Medical, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quoin Pharmaceuticals	0	0	2	0	3.00
ShockWave Medical	1	2	5	0	2.50

Quoin Pharmaceuticals presently has a consensus target price of $17.50, suggesting a potential upside of 3,025.00%. ShockWave Medical has a consensus target price of $248.22, suggesting a potential upside of 29.35%. Given Quoin Pharmaceuticals’ stronger consensus rating and higher possible upside, research analysts plainly believe Quoin Pharmaceuticals is more favorable than ShockWave Medical.

Volatility & Risk

Quoin Pharmaceuticals has a beta of 1.69, indicating that its share price is 69% more volatile than the S&P 500. Comparatively, ShockWave Medical has a beta of 0.97, indicating that its share price is 3% less volatile than the S&P 500.

Summary

ShockWave Medical beats Quoin Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

About Quoin Pharmaceuticals

(Get Rating)

Quoin Pharmaceuticals Ltd. is a specialty pharmaceutical company engaged in the development of therapeutic products for the treatment of rare and orphan diseases. The company was founded on March 5, 2018 and is headquartered in Kefar Sava, Israel.

About ShockWave Medical

(Get Rating)

Shockwave Medical, Inc. operates as a medical device company, which focuses on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. The firm offers M5 catheters for treating above-the-knee peripheral artery disease, C2 catheters for treating coronary artery disease, and S4 catheters or treating below-the-knee peripheral artery disease. The company was founded by Daniel Hawkins, John M. Adams, and Todd J. Brinton in 2009 and is headquartered in Santa Clara, CA.